“Appendix 3B New issue announcement, application for quotation of additional securities and agreement” of 19 June, 2018 is posted.
View and download Appendix 3B New issue announcement, application for quotation of additional securities and agreement of 19 June, 2018.
Phase 2 HER2 Clinical Trial Manufacturing Commenced, WSU Imaging Optimisation Program Underway
September 9, 2025
Highlights Dr Nina Webster appointed as IBX Non-Executive Director, bringing significant clinical development expertise and corporate experienceto the IBX Board ahead of HER2 Breast cancer